Alexis K. Williams

Alexis K. Williams

Auto-generated profile, based on publicly available information

Alexis K. Williams

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
JMJesse Martin
Jesse Martin
AWAlexis K. Williams
Alexis K. Williams
MKMelissa D. Klein
Melissa D. Klein
VSVindhya B. Sriramoju
Vindhya B. Sriramoju
SMShivanshu Madan
Shivanshu Madan
CLCraig R. Lee
Craig R. Lee

1 July 2020 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
MGMegan N Gower
Megan N Gower
LRLindsay R Ratner
Lindsay R Ratner
AWAlexis K Williams
Alexis K Williams
JRJoseph S Rossi
Joseph S Rossi
GSGeorge A. A Stouffer
George A. A Stouffer
CLCraig R Lee
Craig R Lee
In patients undergoing percutaneous coronary intervention (PCI), the standard of care is dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin. Current clinical practice guidelines now recommend more potent P2Y12 inhibitors (prasugrel or ticagrelor) over clopidogrel in acute coronary syndrome (ACS). However, clopidogrel remains the most commonly prescribed P2Y12 inhibitor in the setting of PCI and is also the preferred agent in the treatment and secondary prevention of stroke. Clopidogrel is a prodrug that requires bioactivation by the CYP2C19 enzyme. It has been shown that clopidogrel use in patients who are CYP2C19 no function allele carriers are associated with impaired antiplatelet inhibition and a higher risk of major adverse cardiovascular and cerebrovascular events. Compared to clopidogrel, prasugrel and ticagrelor clinical response is not impacted by CYP2C19 genotype. Even with a demonstrated increased risk of adverse outcomes in CYP2C19 no function allele carriers treated with clopidogrel, routine implementation of CYP2C19 genotyping to guide antiplatelet therapy selection has remained controversial and has not been widely adopted. Recent results from multiple prospective randomized and nonrandomized clinical trials investigating the use of CYP2C19 genotype-guided antiplatelet therapy following PCI have advanced the evidence base demonstrating the clinical utility of this strategy. Multiple recent studies have examined the effects of CYP2C19 genotype on clopidogrel outcomes in the setting of stroke and neurointerventional procedures. In this review, we discern the clinical utility of using CYP2C19 genotype testing to guide antiplatelet therapy prescribing by evaluating the impact of CYP2C19 genotype-guided selection of antiplatelet therapy on clinical outcomes, summarizing emerging data from cardiovascular and neurology clinical studies, and discussing implications for clinical practice guidelines, remaining knowledge gaps and future research directions.